ARTICLE | Clinical News
TPIV200/huFR-1: Phase II started
June 27, 2016 7:00 AM UTC
TapImmune began an open-label, U.S. Phase II trial to evaluate 2 dose levels of intradermal TPIV 200 with or without cyclophosphamide in about 80 patients with stage IIb or III TNBC. Patients will rec...